A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/19/2002	WO2002057222A3 Thiol-based naaladase inhibitors
12/19/2002	WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002042248A3 Naphthalene derivatives
12/19/2002	WO2002024727A3 New inhibitors of iapp fibril formation and uses thereof
12/19/2002	WO2001047919A9 Substituted oxazolidinones and their use in the field of blood coagulation
12/19/2002	WO2000058303A9 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
12/19/2002	US20020193855 Patient temperature regulation method and apparatus
12/19/2002	US20020193634 Disulfide derivatives useful for treating allergic diseases
12/19/2002	US20020193633 Mast cell stabilizers
12/19/2002	US20020193614 Treatment of cardiovascular disorders
12/19/2002	US20020193605 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
12/19/2002	US20020193603 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
12/19/2002	US20020193601 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
12/19/2002	US20020193600 Preparing anhydrous 4-(4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha- dimethylbenzene acetic acid hydrochloride by azeotropic distillation of the corresponding hydrate
12/19/2002	US20020193595 Agonists of the melanocortin-4 receptor ("MC-4r"); useful treating obesity and type 2 diabetes
12/19/2002	US20020193590 Tetra- or hexa-hydroazepine compounds substituted at the 4 position with benzofur-7-yl, indol-7-yl, or benzo(b)thiophen-7-yl; antidepressants
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193561 P53 protein variants and therapeutic uses thereof
12/19/2002	US20020193446 Compounds and methods for the inhibition of the expression of VCAM-1
12/19/2002	US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002	US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002	US20020193431 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
12/19/2002	US20020193418 Methods of using and preparing thiolutin dioxide
12/19/2002	US20020193412 Compounds and compositions for treating tissue ischemia
12/19/2002	US20020193410 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
12/19/2002	US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002	US20020193406 Novel compound
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002	US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002	US20020193375 Heterocyclic derivatives which inhibit factor Xa
12/19/2002	US20020193367 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
12/19/2002	US20020193364 For therapy of central nervous system (CNS) diseases
12/19/2002	US20020193360 For enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease
12/19/2002	US20020193357 Liver X receptor agonists
12/19/2002	US20020193326 Methods of inhibiting proliferative diseases
12/19/2002	US20020193317 Using smilagenin, prazerigenin, an astragaloside, tigogenin, ruscogenin, hecogenin and diosgenin in manufacture of medicament for therayp of condition characterised by deficiency in postsynaptic membrane-bound receptor number
12/19/2002	US20020193315 Having inhibitory activity against diacylglycerol acyltransferase and useful for therapy and prophylaxid of disease of humans such as obesity or hyperlipidemia which is caused by accumulation of triacylglycerol
12/19/2002	US20020193311 Novel cytostatic conjugates with integrin ligands
12/19/2002	US20020193309 Contacting the sample or tissue with fibroblast growth factor 9 (FGF9) and allowing formation of receptor-ligand pairs; detecting presence of FGFR3-FGF9 pairs, a positive detection indicating presence of FGFR3 in the sample or tissue
12/19/2002	US20020193307 Antagonism of endothelin actions
12/19/2002	US20020193302 Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
12/19/2002	US20020193288 Methods of treating hypertension and compositions for use therein
12/19/2002	US20020192826 Recombinant AAV vector-based transduction system and use of same
12/19/2002	US20020192822 Herpes simplex virus ICP4 is an inhibitor of apoptosis
12/19/2002	US20020192801 Human uridine diphosphate galactose-4-epimerase
12/19/2002	US20020192760 Nucleotide sequences coding membrane protein for use the diagnosis and treatment of asthma, parkinson's, heart defects, hypotension, urogenital disorders
12/19/2002	US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002	US20020192729 Apoptosis protein for use in the diagnosis and treatment of cell proliferative disorders
12/19/2002	US20020192709 Detection of modulators of receptor binding activity; obtain sample containing receptor, incubate with modulator, monitor adjustment of binding activity of receptor
12/19/2002	US20020192695 Detection of modulator of tumor suppressor activity; obtain sample of polypeptide, incubate with modulator, monitor adjustment in polypeptide activity
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192313 Use of legume products for the treatment of external aggressions
12/19/2002	US20020192305 Inflammatory mediation obtained from atractylodes lancea
12/19/2002	US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002	US20020192282 Multilayer pharmaceutical product for release in the colon
12/19/2002	US20020192280 Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
12/19/2002	US20020192276 Use of G class immunoglobulins for the topical treatment of atopic dermatitis
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192189 AAV transduction of myoblasts
12/19/2002	DE10127712A1 Use of immunoglobulin M for treatment and prevention of systemic lupus erythematosus, administered subcutaneously or intramuscularly
12/19/2002	CA2450720A1 In vivo bioreactors
12/19/2002	CA2450400A1 Medicinal compositions
12/19/2002	CA2450379A1 Molecular signatures of commonly fatal carcinomas
12/19/2002	CA2450316A1 Cd10-activated prodrug compounds
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450271A1 Novel phenylalkyl diamine and amide analogs
12/19/2002	CA2450269A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450265A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450262A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
12/19/2002	CA2450240A1 Treatment and composition for wound healing
12/19/2002	CA2450205A1 Aminediols for the treatment of alzheimer's disease
12/19/2002	CA2450167A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	CA2450131A1 Respiratory syncytial virus
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449948A1 Methods of treating alzheimer's disease
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449687A1 Vascular regeneration therapy
12/19/2002	CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	CA2449573A1 Bmp binding proteins for use in bone or cartilage regeneration
12/19/2002	CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	CA2449259A1 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
12/19/2002	CA2449249A1 Nr2b receptor antagonists for the treatment or prevention of migraines
12/19/2002	CA2449247A1 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	CA2449213A1 Ophthalmic compositions comprising hyaluronic acid
12/19/2002	CA2448763A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
12/19/2002	CA2448552A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	CA2447763A1 Methods for improving cell line activity in immunoisolation devices
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	CA2445653A1 Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
12/19/2002	CA2445471A1 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotic acetylcholine receptors
12/19/2002	CA2445467A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266896A1 Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266888A1 Quinoline derivatives and medicinal use thereof
12/18/2002	EP1266663A1 Eosinophil-specific apoptosis inducer

1 ... 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 ... 1564